Jerusalem, G., Farah, S., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Gombos, A., Courtois, A., Ruhstaller, T., Burstein, HJ, Rabaglio, M., Ruepp, B, Ribi, K, Viale, G, Gelber, RD, Coates, AS, Loi, S, Goldhirsch, A, Chirgwin, J., Regan, MM, Colleoni, M, Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E.. Elsevier; 2021. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

McCarthy, N., Boyle, F., Gebski, V., Veillard, A. S., Zannino, D., Wilcken, N., Reaby, L., Lindsay, D. F., Badger, H. D., Forbes, J. F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P. A., Chirgwin, J., Abdi, E.. Elsevier; 2014. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).

Hovey, E., Lloyd, A., Abdi, E., de Souza , P., Marx, G., Parente, P., Rapke, T., Hill, A., Bonaventura, A., Michele, A., Craft, P.. Springer; 2014. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.